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mI t is common for medical categories to be heter-ogeneous. A classic example is leukemia: thereare different kinds of leukemias, each with a
different etiology and a different clinical course.
Disruptive behavior disorders seem an analogous
example from child and adolescent psychiatry.
Previous work has suggested that disruptive
behaviors are made up of distinguishable dimen-
sions of feelings and behaviors (such as callous and
unemotional traits or irritable mood). In this issue
of the Journal, Wakschlag and colleagues (p. 593)
are taking this approach further in two important
ways. First, they are examining preschoolers, an
underinvestigated age group. Second, the investi-
gators have a clear theory that they set out to test by
examining the fit of different models. They find
that their approach of separating out the heteroge-
neity within disruptive behavior disorders is supe-
rior to the three competing models (including the
conduct disorder/oppositional defiance disorder
distinction present in DSM-IV). In particular, the
investigators provide evidence that disruptive be-
havior disorders in preschool children may be best
seen as comprising four distinguishable dimen-
sions of feelings and behaviors: temper loss, non-
compliance, aggression, and low concern for oth-
ers. The investigators examine the reliability and
validity of their distinctions using two different
samples (one clinic based and the other community
based), which helps solidify their findings. One of
the important next steps, as the investigators also
remark, will be ways that could help exploit these
insights for clinical practice.
Another source of heterogeneity can be the way
in which psychiatric problems are measured. This
is a methodologic source of heterogeneity that can
have profoundly negative implications—subjects
may have the same diagnostic labels but be dissim-
ilar in their symptom profiles and, thus, study
findings may be inconsistent. The study by Gal-
anter and colleagues (p. 605) in this issue of
the Journal attempts to tackle this major question
for bipolar disorder. As every child psychiatrist
knows, some of the hardest problems in assessing t
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VOLUME 51 NUMBER 6 JUNE 2012ipolar disorder include how to establishwhether a
hild’s irritability is episodic rather than a trait,
hen exactly an episode started, how long such an
pisode lasted, how exactly to establish episodicity
a change in baseline), and which of the potentially
anic symptoms (e.g., grandiosity or disinhibition)
ere present during this very episode of a change
n mood. The review by Galanter and colleagues
hows that there are ambiguities in DSM-IV-TR
ania criteria and that these are reflected in the
ifferent ways in which psychiatric instruments
ssess these problems. The investigators conclude
ith a list of clear recommendations on how to best
ssess bipolar disorder for future instruments and
he DSM-5. The investigators also discuss issues
hat relate to the minimum training required for
eople to use such instruments and the best ways
o reach consensus about these matters in the field.
Differences in pathophysiologic processes can
nderlie heterogeneity. Strawn and colleagues (p.
42) in this issue of the Journal use magnetic reso-
ance spectroscopy to show that brain glutamate
evels may predict whether divalproex sodiumwill
e successful for the treatment of mania in adoles-
ents. The investigators found that glutamate levels
n patients were no different from those in healthy
olunteers at baseline. However, patients with
ower glutamate levels in the left ventrolateral
refrontal cortex, an area implicated in mood reg-
lation, were more likely to remit after treatment
ith divalproex. Moreover, improvements on the
n the Youth Mania Rating Scale correlated posi-
ively with changes in glutamate concentrations in
emitting patients. The findings are important for
wo reasons. First, they demonstrate a potential
ource of person-specific heterogeneity in treat-
ent outcome—brain glutamate levels. Second,
hey remind us that measuring such markers is
easible in vivo using magnetic resonance spectros-
opy. The clinical utility of such a measurement
nd the extent to which baseline glutamate levels
ay be aworthwhile target for intervention remaino be examined.
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T reatment response can vary within individ-uals who have the same diagnostic labelbecause of heterogeneity. Severity is yet
another source of heterogeneity and it is often
thought to influence treatment response in psy-
chiatric disorders such as depression. Gibbons
and colleagues1 used person-level longitudinal
data from the first 6 weeks of treatment of
antidepressant trials for adolescents, adults, and
geriatric patients. They reported several impor-
tant findings. Firstly, antidepressants were effec-
tive for the treatment of depression in any age
group. Secondly, the response and remission
rates were largest for adolescents. For example,
46.6% had a remission on fluoxetine versus 16.5%
of adolescents treated with placebo, amounting
to a number needed to treat of 3.33. Thirdly, there
was no evidence that severity had an influence
on treatment outcome: patients with low or high
severity responded to a similar extent.
These findings lead to another, more general,
question: How well do treatments work for psy-
chiatric patients? Questions about the heteroge-
neity of psychiatric phenotypes and the relatively
sparse knowledge about the etiology of psychi-
atric disorders typically come with concerns
about the efficacy of the treatments psychiatrists
offer. Thus far, little has been done to address
this issue in an empirical manner. In a recent
article, Leucht and colleagues2 reformulated the
question as follows: How well do psychiatric
treatments work compared with treatments in
other medical disciplines? To answer this ques-
tion, the investigators conducted a review of 94
meta-analytic studies of drugs compared with
placebo for common medical and psychiatric
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first was that, overall, psychiatric drugs were no
less efficacious than other drugs. An example
that puts this in perspective is that the acute
treatment of schizophrenia with antipsychotics
led to a standardized mean difference of around
0.5 compared with 0.11 for the thrombolysis of
acute stroke and 0.56 for the treatment of asthma
with corticosteroids. The second finding is of
particular interest to child psychiatrists: the treat-
ment of attention-deficit/hyperactivity disorder
was the most efficacious overall, with a standard-
ized mean difference of 0.78.
These are encouraging findings for the field of
child and adolescent psychiatry and for what it
has to offer to young patients. However, there is
still a lot of work ahead. A particular challenge is
using evidence-based treatments for as many
patients as possible. In other areas of medicine—
such as cancer treatment—this is achieved by
including most patients in ongoing large-scale
trials. Doing so not only advances pharmacother-
apy (this is the way to rigorously test medica-
tions) but also improves patients’ outcomes be-
cause it is known that those taking part in trials
do better than those who do not participate in
trials.3
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